A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Study of SB-681323 (a novel p38 MAPkinase inhibitor) in subjects with documented coronary heart disease (CHD) undergoing elective percutaneous coronary intervention (PCI).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Females must be of non-child-bearing potential.

• Female subjects must have a negative pregnancy test.

• Subjects scheduled to undergo elective single vessel PCI to be performed within the 6 weeks of diagnostic coronary angiography.

• Must be on stable dose of statin for = 6 weeks prior to screening, with statin tolerability and LDL <130 mg/dL (3.4 mmol/L) at Screening visit.

• Must be capable of providing informed consent.

• Have an hsCRP concentration of >2 mg/L, but < 10 mg/L at screening.

Exclusion Criteria:

• Women who are pregnant or breast feeding.

• Planned PCI with multi-vessel stenting.

• Planned PCI with additional revascularization procedures staged at different days during the study period.

• Planned PCI other than stenting (e.g., atherectomy, PTCA without stenting, etc).

• Planned PCI of any bypass graft.

• History of CABG surgery.

• Planned cardiac or major non-cardiac surgery within the study period.

• Disabling stroke in the past 6 months.

• History of chronic viral hepatitis or other chronic hepatic disorders.

• History of Gilbert's syndrome or elevated bilirubin concentrations at screening.

• History of increased liver function tests (ALT, AST) due to acute or chronic liver conditions, above the upper limit of normal at screening or in the past 6 months.

• Renal impairment with serum creatinine >2.0 mg/dl (177umol/L) at Screening, or history of kidney transplant, or a history of contrast nephropathy.

• Current inadequately controlled hypertension (blood pressure >160 mmHg systolic and/or >100 mmHg diastolic) on a stable dose of antihypertensive medication.

• Current poorly controlled diabetes mellitus, defined as HbA1c >10% at Screening.

• History of severe heart failure defined as NYHA class III or IV or those with known severe LV dysfunction (EF<30%) regardless of symptomatic status.

• History of malignancy within the past 5 years, other than non-melanoma skin cancer.

• Current life-threatening condition other than vascular disease that may prevent a subject from completing the study.

• Alcohol or drug abuse within the past 6 months.